Ms. Wong often serves as outside general counsel to life sciences companies as they develop, in-license and acquire intellectual property and other assets, raise capital to fund their operations and seek to partner their technology or engage in exit transactions. She has represented biotechnology, medical device, diagnostics and specialty pharmaceutical companies and their investors on a range of corporate and transactional matters.
- aTyr Pharma, Inc. in its $76 million Series E Preferred Stock financing
- Cleave Biosciences, Inc. in its $54 million Series A Preferred Stock financing and $37 million Series B Preferred Stock financing
- Delinia, Inc. in its $35 million Series A Preferred Stock financing
- Global Blood Therapeutics, Inc. in its $40.7 million Series A Preferred Stock financing and $48 million Series B Preferred Stock financing
- MyoKardia, Inc. in its $46 million Series B Preferred Stock financing
- Spinifex Pharmaceuticals, Inc. in its $45 million Series C Preferred Stock financing
- Baird Venture Partners in multiple portfolio investments, including Zurex Pharma Inc. and Insightra Medical Inc.
- Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 million and $125 million follow-on public offerings
- MyoKardia in its $54 million initial public offering and $65 million follow-on offering
- aTyr Pharma, Inc. in its $75 million initial public offering
- Fate Therapeutics, Inc. in its initial public offering, subsequent follow-on public offering and private placement transactions
- Underwriters in the initial public offering and a subsequent follow-on offering of Regulus Therapeutics Inc.
- Underwriters in the initial public offering of Conatus Pharmaceuticals Inc.
- Delinia, Inc. in its sale to Celgene Corporation for $300 million upfront and $475 million in milestone payments
- F-star Alpha Ltd in its exclusive option agreement with Bristol-Myers Squibb for aggregate consideration of up to $475 million
- Spinifex Pharmaceuticals in its $200 million upfront sale to Novartis International AG plus undisclosed clinical development and regulatory milestones
- Artisan Pharma, Inc. in its sale to Asahi Kasei Pharma Corp. for an undisclosed amount
- Assembly Pharmaceuticals, Inc. in its merger with Ventrus Biosciences, Inc. to become Assembly Biosciences, Inc. (NASDAQ: ASMB)
- Gallus Biopharmaceuticals, LLC in its acquisition from Centocor Biologics, a subsidiary of Johnson & Johnson, of an FDA-approved, commercially certified biologics manufacturing facility and its entry into an agreement for the commercial manufacture of Remicade and Stelara
- Alere Inc. in its acquisition from ACON Laboratories, Inc. of ACON’s worldwide lateral flow immunoassay diagnostics business
- A major buyer of pharmaceutical royalties in the acquisition of a royalty interest from a private university for over $90 million
Ms. Wong is a member of the American Bar Association and the San Francisco Bar Association.
Prior to joining Goodwin, Ms. Wong was an associate in the corporate practice group at Heller Ehrman LLP, where she focused her practice on the representation of emerging companies. Before that, she was an associate in the business law department at Cooley LLP. During law school, Ms. Wong was a summer intern in the Office of the General Counsel of the U.S. Securities and Exchange Commission in Washington, D.C.